Medical Hypotheses
Volume 59, Issue 3 , Pages 314-315 , September 2002

Matrixmetalloproteinase inhibitor therapy to prevent complications as well as therapy for Ehler–Danlos syndrome

  • P.S.R.K Sastry

      Affiliations

    • Corresponding Author InformationCorrespondence to: Dr. P.S.R.K. Sastry MD, Consultant Medical Oncologist and Bone marrow transplant physician, Jaslok Hospital and Research Centre, 15, D.G. Deshmukh Marg (Pedder Road), Mumbai (Bombay), India. Fax: +91-22-4950508

Received 9 October 2001 ,Accepted 20 December 2001.

References 

  1. Esterly NB. In: Vaughan , Behrman  editor. Nelson's text book of pediatrics. 13th Edn.. London: W.B. Saunders; 1987;
  2. Prockop DJ, Kuivaniemi H, Tromp G, Ala-Kokko L. In: Braunwald, Fauci, Kasper, Hauser, Longo, Jameson (eds). Inherited Disorders of Connective Tissue. Harrison's Principles of Internal Medicine, Vol. 1, Chapter 351. New York: McGraw-Hill. 2296–2297; 2000
  3. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JAC. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomised trial. J. Clin. Oncol. 2001;19:3447–3455
  4. Bertolini F, Mingrone W, Alietti A, et al.  Thalidomide in multiple myeloma myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. Ann. Oncol. 2001;12(7):987–990
  5. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastases. J. Natl. Cancer Inst. 1997;89:1260–1270
  6. Zucker S, Cao J, Chen W-T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene. 2000;19:6642–6650

PII: S0306-9877(02)00175-5

Medical Hypotheses
Volume 59, Issue 3 , Pages 314-315 , September 2002

Article Tools